New: Our latest case study on qFibrosis' role in the successful development of Rezdiffra

AI Digital Pathology for Fibrosis in MASH and MAFLD

Refining Pathology's Lens

We unveil unprecedented insights into fibrosis on tissue biopsies using our stain-free, AI-based digital pathology platform, enabling our partners to accelerate therapeutics.

SHG Image of Fibrosis in a Liver Biopsy. Collagen in Green, Hepatocytes and Immune Cells in Red

Stain-free Imaging and AI Image Analysis

Augmenting Fibrosis Analysis

Our proprietary technology integrates label-free Second Harmonic Generation imaging and explainable AI to consistently visualize and quantify subtleties within biological tissues that conventional methods miss. By analyzing key morphological and architectural markers, we provide translatable data from preclinical studies to clinical trials.

Accelerating Therapeutic Development for Fibrosis

Mining Deep Data with Digital Pathology

Our imaging and analysis services accelerate advancements and regulatory approvals across the drug development and clinical diagnostic value chain.

Transforming Phase 1 results to Phase 2 and 3 studies

Preclinical to Clinical Translatability

Improving clinical trial design and data reporting

Enhancing Clinical Trial Efficiency and Success

Designing Companion Diagnostics

Clinical Diagnostics Development

"[HistoIndex’s data] corroborates what the primary endpoint shows and it takes a deeper dive into what really is happening. These patients actually demonstrate even better results when qFibrosis is utilized. There are also significant correlations between reduction in qFibrosis and reduction to PDFF, ALT, AST, and ELF score.”
Dr. Stephen Harrison
Dr. Stephen Harrison
Lead Principal Investigator of the MAESTRO studies for Rezdiffra™ (resmetriom), first FDA-approved medication for MASH

Digitizing Healthcare

Through evidence-based studies, we are pushing the boundaries to algorithmize decision-making from drug development to precision diagnosis, to prediction of disease progression, and subsequently, life-changing therapies personalized to each patient. Discover how our stain-free, AI digital pathology platform can support your objectives.